WALTHAM, Mass. & SAN DIEGO -- Cerulean Pharma Inc. (NASDAQ:CERU) and Daré Bioscience, Inc. today announced that Daré Founder and CEO Sabrina Martucci Johnson mailed the following letter to Cerulean stockholders of record at the close of business on June 9, 2017 outlining the Daré value proposition and requesting they vote FOR all of the management proposals at the upcoming special meeting of stockholders to be held on July 19, 2017:

 

Dear Cerulean Stockholder,

As the founder and CEO of Daré Bioscience, Inc. (“Daré”), I am excited by the prospect of Daré combining with Cerulean Pharma Inc. (“Cerulean”). Daré is a healthcare company committed to the development and commercialization of innovative products in women’s health. We believe a segment of this market is underserved, which gives us an opportunity to create value for stockholders.

WOBURN, Mass., June 27, 2017 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced that the Company’s novel C4001 trait, a global regulatory gene or transcription factor, has been shown to significantly increase plant biomass yield in switchgrass.  Yield10’s Chief Science Officer Kristi Snell, Ph.D., will be presenting data today at the Plant Biology 2017 Conference. The C4001 trait was identified using Yield10’s T3 Platform, a novel method for gene discovery.

 

At the conference, Dr. Snell will describe the performance of the C4001 trait in switchgrass plants, a model plant system that Yield10 has used for gene discovery and evaluation, as well as the effect of expression of C4001 on photosynthesis.  Switchgrass plants expressing C4001 had significantly more aboveground biomass (75-100% increase in dry weight) as compared to controls and more root biomass (85-145% increase in dry weight) as compared to controls. 

BEIJING, June 26, 2017  -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has entered into a definitive amalgamation agreement (the "Amalgamation Agreement") with Sinovac (Cayman) Limited ("Parent") and Sinovac Amalgamation Sub Limited ("Amalgamation Sub"), a wholly owned subsidiary of Parent, pursuant to which Sinovac will be acquired by Parent in a transaction valued at approximately US$401.8 million.

- Pharmacokinetic data supports previous preclinical results, demonstrating an extended product residency time at the site of epidural injection

- Single epidural injection of SP-102 resulted in sustained analgesic effect, lasting over the entire observational period of one month

- SP-102 is a novel injectable gel formulation containing no particulates, solids, surfactants or preservatives in the drug product

 

LOS ALTOS, Calif., June 26, 2017  -- Semnur Pharmaceuticals, Inc. ("Semnur") today announced successful Phase 1 / 2 pharmacokinetic bridging trial of the lead product SP-102.  The trial was conducted in the patients with radicular pain, achieved its primary pharmacokinetic endpoint, and also demonstrated that a single epidural injection of SP-102 can lead to a sustained analgesic effect lasting one month.